Rationale: Vascular endothelial growth factor (VEGF) affects angiogenesis, atherosclerosis, and cancer. Although the heritability of circulating VEGF levels is high, little is known about its genetic underpinnings.
V ascular endothelial growth factor (VEGF, also referred to as VEGFA in contrast to other members of the VEGF family) is pivotal in many physiological and pathological processes. 1 It is primarily known for its key role in the stimulation of angiogenesis, with a potent mitogenic effect on vascular endothelial cells from arteries, veins, and lymphatics. 2 VEGF also promotes vasodilatation by inducing the production of nitric oxide and prostacyclin by endothelial cells. 3 In addition, VEGF is involved in hematopoietic development and chemotaxis of monocytes, regulation of osteoclast differentiation, and stimulation of surfactant production 1 and has neurotrophic and neuroprotective effects on neuronal and glial cells. 4 Elevated circulating VEGF levels have been observed in vascular disease (ischemic heart disease, 5, 6 heart failure, 7 stroke 8 ) and in various other disorders, including diabetes, 9 cognitive decline and dementia, 10, 11 reproductive, [12] [13] [14] immune-inflammatory disorders, 15, 16 and neoplastic diseases. 17, 18 Administration of VEGF promotes angiogenesis in patients with critical leg ischemia as well as in animal models of coronary and limb ischemia. 19 VEGF inhibitors such as bevacizumab and sorafenib have been successfully used to inhibit angiogenesis in several tumors, 20, 21 in macular degeneration, 22 and in rheumatoid arthritis. 23 However, despite the considerable toxicity associated with VEGF inhibitor drugs, 24 there have been no pharmacogenomic studies to identify potential subgroups of responders, partly because the genetic determinants of VEGF concentrations remain poorly understood.
Indeed, although the heritability of circulating VEGF levels is very high, ranging between 60% and 80%, [25] [26] [27] few studies have assessed the relation between circulating VEGF levels and genetic variants, yielding inconsistent results. The aim of the present study was to identify genetic variants associated with circulating VEGF levels using an unbiased genome-wide approach in a large community-based sample.
Methods

Study Populations
The Framingham Heart Study
The Framingham Heart Study (FHS), initiated in 1948, is a 3-generation, community-based, prospective cohort study conducted in Framingham, MA. [33] [34] [35] Serum VEGF levels were measured in third-generation cohort participants (2002 to 2005), and genomewide genotyping was performed on these individuals at Affymetrix (Santa Clara, CA) through a National Heart, Lung, and Blood Institute-funded SNP-Health Association Resource (SHARe) project. We chose not to include participants with cardiovascular disease because it may influence VEGF levels. After excluding participants who had prevalent cardiovascular disease, which may influence their VEGF levels, or who failed to meet quality control standards, 3527 participants were enrolled.
The STANISLAS Family Study
The STANISLAS Family Study (SFS) is a 10-year, longitudinal survey involving 1006 volunteer families from Vandoeuvre-lès-Nancy, France, whose members were free of chronic disease (cardiovascular or cancer) between 1993 and 1995. 28 Plasma VEGF levels were measured at the second examination cycle (1998 to 2000) in a randomly selected subsample; of these, 859 persons from 217 families, who also had DNA and met genotyping quality control criteria, were included.
Prospective Investigation of the Vasculature in Uppsala Seniors Study
The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study is a population-based study that enrolled 1016 70-year-old individuals living in the community of Uppsala, Sweden (2001 to 2004). 29 Of these, 999 persons provided DNA for genetic studies, and, after exclusions for prevalent cardiovascular disease and inadequate genotyping quality, 868 participants were eligible.
Further details of the study samples are available in the Online Supplemental Methods, section I at http://circres.ahajournals.org.
Laboratory Measurements of VEGF Levels
VEGF levels were measured in serum for the FHS and PIVUS and plasma for the SFS (Online Supplemental Methods, section II).
Genotyping
Framingham Heart Study
Genome-wide genotyping in the FHS was performed on the Affymetrix GeneChip Human Mapping 500K Array Set and 50K Human Gene Focused Panel. Genotyping, quality control, and imputation methods are detailed in the Online Supplemental Methods, section III.
STANISLAS Family Study
The single nucleotide polymorphisms (SNPs) were genotyped by Genoscreen (http://genoscreen.fr), using a Sequenom iPLEX Gold assay-Medium Throughput Genotyping Technology. 30 
PIVUS Study
The SNPs were genotyped as part of a 96-plex assay at the SNP technology platform in Uppsala University (http://www.genotyping.se/), using the Illumina BeadXpress system from Illumina Inc. 31 Genotyping calls were done with Illumina BeadStudio software.
Statistics
VEGF levels were natural log-transformed to normalize their distribution.
Genome-Wide Association Analysis in the FHS
A linear mixed effects model accounting for familial relatedness was used to evaluate the association of each SNP with VEGF levels. 32 An additive genetic model with 1 degree of freedom was used. In a first step (model A), analyses were adjusted for age, sex, and the ninth principal component (Online Supplemental Methods, section IV). In a second step designed to explore potential mechanisms, we additionally adjusted our most significant associations for covariates previously found to be associated with serum VEGF levels 25 : Compared with model A, model B was additionally adjusted for hypertension; model C for smoking; model D for central obesity; and model E for the presence of a metabolic syndrome (Online Supplemental Methods, section V).
Genetic Association Study in the SFS and the PIVUS Studies
To confirm our findings in the FHS, we genotyped 25 SNPs in 2 independent samples. To select a parsimonious number of SNPs for replication, we used criteria of strength of association (probability value), whether the SNP was genotyped or imputed, linkage disequilibrium (LD) between SNPs and functionality (Online Supplemental Methods, section VI). A linear regression model using the same covariates and analytic strategy as in the FHS was implemented.
Non-standard Abbreviations and Acronyms
FHS
Framingham Heart Study GWAS genome-wide association study For SNPs that were successfully genotyped in the SFS and the PIVUS study, we performed a meta-analysis of the SNP-phenotype associations, using a fixed-effects inverse-variance meta-analysis technique for the combination of results from the FHS and the PIVUS study (which had both measured VEGF levels in the serum) and an effective sample size-weighted meta-analysis for the combination of results from all 3 studies to account for the different scales of VEGF levels in serum and plasma (Online Supplemental Methods, section VII).
IPA
Genetic Score
The methods used for computing a genetic score are detailed in the Online Supplemental Methods, section VIII, and Online Table I . The phenotypic variance explained by this genetic score was separately calculated in the FHS, the SFS, and the PIVUS study, using regression models that included age and sex as covariates.
VEGF Gene Expression Analysis in Peripheral Blood Mononuclear Cells
Sample preparation and quantification of the peripheral blood mononuclear cells (PBMCs) messenger RNA (mRNA) of VEGF spliced forms and statistical analyses of these data are described in the Online Supplemental Methods (section X).
Biological Pathway Analysis
Methods for the biological pathway analysis are provided in the Online Supplemental Methods, section IX.
Results
Characteristics of the 5273 study participants are presented in Table 1 .
Genome-Wide Association Study of VEGF Levels in the FHS
The quantile-quantile plot showed an excess of extreme probability values but no evidence of systematic inflation of the genomic control inflation factor (ϭ1.02) (Online Figure  I ). The genome-wide plot of probability values for the individual SNPs against their genomic position is shown in Online Figure II . A total of 140 SNPs cleared the threshold for genome-wide significance at 5ϫ10 Ϫ8 (Online Table II ). These were located in 3 chromosomal regions: 6p21.1, 8q23.1, and 9p24.2 ( Table 2 ). The most significant association was found with rs6921438 on chromosome 6p21.1 (Pϭ6.11ϫ10 Ϫ506 ), at 171 kb downstream of the VEGF gene, and close to the mitochondrial ribosomal protein L14 gene (MRPL14) and the MCG45491 gene (C6orf223), encoding an uncharacterized protein. Sixty-seven other SNPs on chromosome 6p21.1 were also associated with VEGF levels at PϽ5ϫ10 Ϫ8 ( Figure 1A ). When running a conditional genome-wide association study (GWAS) adjusting for rs6921438, 1 other SNP in 6p21.1 (rs4416670) still yielded a genome-wide significant association, suggesting that 2 variants in this region independently modulate VEGF levels. In the 8q23.1 region, the SNP yielding the most significant association with VEGF levels (rs6993770, Pϭ2.50ϫ10 Ϫ16 ) is located in the zinc finger protein, multitype 2 (ZFPM2) gene and 980.4 kb away from the low-density lipoprotein receptor-related protein 12 gene (LRP12). Forty-three SNPs in LD with rs6993770 were also associated with VEGF levels at PϽ5ϫ10 Ϫ8 ( Figure 1B) . A conditional GWAS adjusting for rs6993770, rs6921438, and rs4416670 did not yield any other genome-wide significant association in chromosome 8q23.1. The most significant association on 9p24.2 was observed with rs10738760 (Pϭ1.96ϫ10 Ϫ34 ), located close to the very low-density lipoprotein receptor (VLDLR) and potassium voltage-gated channel subfamily V, member 2 (KCNV2) genes. Twenty-nine SNPs in LD with rs10738760 were also associated with VEGF levels at PϽ5ϫ10 Ϫ8 ( Figure  1C ). None reached genome-wide significance in a conditional GWAS adjusted for rs6921438, rs4416670, rs6993770, and rs10738760.
We computed a genetic score including the 4 SNPs yielding genome-wide significant associations with VEGF levels in the conditional GWAS (Online Table I ). This score explained 47.6% of serum VEGF variability (Pϭ2.19ϫ10
Ϫ644
).
Replication Studies
We sought to replicate our most significant results in 2 independent cohorts. Of the 25 SNPs selected for replication, 24 were successfully genotyped in the SFS and 20 in the PIVUS study (Table 2 ). Of these, 17 and 20, respectively, reached nominal significance in association with VEGF levels, with the same direction of effect (Table 2) . When meta-analyzing the results of the FHS and the PIVUS study, which both used serum VEGF levels, for the 19 SNPs genotyped in both studies, all 19 SNPs were associated with VEGF levels at PϽ0.05 ( Table 2 ). The joint meta-analysis of results from all 3 studies, using an effective sample sizeweighted meta-analysis, is displayed in Table 2 . There was statistically significant heterogeneity between studies for a †By design, SFS participants were free of chronic disorders (cardiovascular or cancer) and had no history of cardiovascular disease at the time of inclusion (VEGF levels and covariates for the present analysis were measured during the second examination cycle in 1998 to 2000); all individuals with cardiovascular disease, defined in the FHS as presence of stroke, congestive heart failure, coronary heart disease, or intermittent claudication, were excluded before analyses in FHS and PIVUS.
few but not all SNPs in each locus, due to differences in effect size, but not in direction of effects (Online Table III ). The genetic score explained 16.6% (Pϭ1.75ϫ10 Ϫ36 ) of observed plasma VEGF variability in the SFS and 48.4% (Pϭ3.31ϫ10 Ϫ180 ) of observed serum VEGF variability in the PIVUS study.
The observed associations remained unchanged in each of the 3 cohorts after adjusting for hypertension, current smoking, central obesity, and metabolic syndrome (Online Table IV ).
VEGF Gene Expression Analysis
To better characterize the functional role of the SNPs identified in the GWAS, we quantified mRNA expression of the 2 splice variants corresponding to the diffusible isoforms of VEGF, VEGF 121 , and VEGF 165 in PBMCs of 220 SFS participants. The association of VEGF mRNA levels with the 24 SNPs successfully genotyped in the SFS was assessed.
At the nominal significance level, 1 SNP on chromosome 6p21.1, 4 SNPs on chromosome 8q23.1, and 1 SNP on chromosome 9p24.2 were associated with VEGF 121 mRNA levels (Table 3) .
Biological Pathway Analysis
With the use of the Ingenuity Pathway Analysis software (IPA, Ingenuity Systems, www.ingenuity.com), we explored functional relationships between VEGF and the genes closest to the SNPs on chromosomes 8q23.1 and 9p24.2 that were significantly associated with circulating VEGF levels. In each case, we selected the genes closest to the identified SNPs, as in Table 2 , to identify plausible biological pathways. We selected 5 focus genes: VEGF, ZFPM2, LRP12, VLDLR, and KCNV2. The IPA network analysis identified relationships among 3 of these 5 focus genes (VEGF, ZFPM2, and VLDLR) as part of a larger network of 35 genes. The probability of finding 3 or more focus genes in a set of 35 genes randomly selected from the Global Molecular Network was Pϭ10 Ϫ8 , suggesting that the presence of 3 of our 5 focus genes in this network was unlikely to occur by chance. In Figure 2 we present a subset of this network, including only interactions between VEGF and the 2 other focus genes in the network, with 2 or fewer intermediate nodes.
Discussion Principal Findings
In this first GWAS of circulating VEGF levels undertaken in 3527 community individuals of European descent, we identified novel genetic associations: 140 SNPs reached genomewide significance. Of these, 4 SNPs were independently associated with VEGF levels (rs6921438 and rs4416670 on chromosome 6p21.1, rs6993770 on chromosome 8q23.1, and rs10738760 on chromosome 9p24.2). We found evidence of replication for selected SNPs in 1727 individuals of European descent from 2 independent community-based samples. The SNPs are located close to the VEGF and MRPL14 genes (chromosome 6p21.1), within the ZFPM2 gene (chromosome 8q23.1), and between the VLDLR and KCNV2 genes (chromosome 9p24.2). In a subset of participants, we found that 6 of 25 selected SNPs yielding genome-wide significant associations with circulating VEGF levels were also associated with VEGF mRNA levels (VEGF 121 splice variant) in PBMCs.
In the Context of the Current Literature
Genetic Association Study
Candidate gene studies exploring associations between VEGF polymorphisms and circulating VEGF levels have yielded controversial results (Online Supplemental Methods, section XI; Online Table V) . Eight studies have found significant associations with candidate polymorphisms (rs699947, rs1570360, rs833061, rs2010963, rs3025039, and Ϫ2549 18bp I/D) in the promoter, 5Ј, and 3Ј untranslated regions of the VEGF gene. [33] [34] [35] [36] [37] [38] [39] [40] However, several other studies did not identify any association with these and other VEGF SNPs (Online Table V) . Using a hypothesis-free genome-wide approach, the present study revealed novel associations with 140 SNPs. Of these, 68 SNPs are located on chromosome 6, approximately 150 kb downstream from the 3Ј end of the VEGF gene, far from previously tested candidate SNPs. Although we do replicate previously described associations of 2 VEGF promoter polymorphisms (rs699947 and rs833061) with serum VEGF levels at PϽ5ϫ10 Ϫ7 (Online Supplemental Methods, section XI; Online Table V; Online Figure III) , none of the SNPs that reached genome-wide significance in our analysis, on chromosome 6p21.1, 8q23.1, and 9p24.2, had been examined previously in relation with circulating VEGF levels.
Transcriptomic Analysis
Although several studies have examined the association of candidate genetic variants with VEGF gene expression in pathological tissues, 41, 42 little is known about the genetic variants influencing VEGF expression in normal cells. Our data suggest that 6 of the SNPs associated with circulating VEGF levels in our GWAS also modulate the expression of the VEGF 121 splice variant in PBMCs of community-based persons. The diffusible VEGF isoforms, VEGF 165 and VEGF 121 , are released by a variety of tumor and normal cells, including PBMCs. 43 VEGF 121 lacks a heparin-binding domain and has a higher migration but lower mitogenic potency than VEGF 165 . 44 
Potential Mechanisms Mediating Observed Genetic Associations
Our data suggest that almost half the inherited component of circulating VEGF levels is explained by genetic variants located downstream from the VEGF gene on chromosome 6p21.1. The conditional GWAS suggests that this region could harbor at least 2 distinct loci that are independently associated with circulating VEGF levels. Although located relatively far from the VEGF gene, results from our transcriptomic analysis indicate that this region could indeed contain functional variants modulating VEGF gene expression.
Genome-wide significant associations with circulating VEGF levels were also identified for SNPs located on chromosomes 8q23.1 and 9p24.2. Although these trans effects explain a much smaller proportion of the heritability of VEGF levels, they provide important clues about the pathways involved in the regulation of VEGF expression. The SNPs on chromosome 8q23.1 are located in introns 4 and 5 of the ZFPM2 gene. This gene encodes a widely expressed member of the Friend of GATA family of transcription factors that modulate the activity of the GATA family proteins, which are important regulators of embryogenesis and also appear to play a significant role in endothelial cell biology. [45] [46] [47] The second closest gene to the SNPs identified on chromosome 8q23.1 is LRP12, encoding a low-density lipoprotein receptor-related protein that interacts with proteins related to signal transduction pathways and is differentially expressed in many cancer cells. The SNPs on chromosome 9p24.2 are located between the VLDLR and KCNV2 genes. VLDLR encodes a lipoprotein receptor involved in the metabolism of apolipoprotein-E-containing triacylglycerolrich lipoproteins. Like VEGF, VLDLR appears to modify the risk of developing age-related macular degeneration, 48 and recent data suggest that VLDLR could play a central role in a network of interacting angiogenic genes activated in response to hypoxia. 49 KCNV2 encodes a member of the potassium voltage-gated channel subfamily V involved in regulation of neurotransmitter release, neuronal excitability, and heart rate. Although the present data do not permit us to formally determine which of these genes underlie the observed SNP associations with circulating VEGF levels, our in silico biological pathway analysis suggests that ZFPM2 and VLDLR are the most likely candidates. Further research is needed to explore the mechanisms underlying the associations of cis-and trans-acting genetic variants with circulating VEGF levels, such as modulation of gene expression, differential splicing, or mRNA degradation.
Strengths and Limitations
The findings from this first GWAS of circulating VEGF levels emphasize the importance of screening for genetic variation modulating biomarker levels not only within and in close proximity to the gene encoding the protein under investigation, but also in more distant potentially regulatory regions, including on other chromosomes. The strength of the observed associations and the fact that we were able to replicate our findings in 2 independent cohorts suggest that these associations are real. This is further supported by the association of several of these genetic variants with VEGF gene expression in PBMCs. Our study also had several limitations. Whereas focusing on white populations of European descent has the advantage of minimizing potential population stratification issues, our findings cannot be generalized to other ethnic groups. We may not have identified the true causal variants but merely SNPs in LD with the latter.
Plasma levels of VEGF were measured in one of the replication cohorts (SFS), whereas serum VEGF levels had been measured in the discovery cohort. Serum VEGF concentrations are higher than plasma concentrations because of the release of VEGF from platelets during the clotting process. 50 Although the vast majority of associations found in the FHS did replicate in the SFS, suggesting an important overlap between genetic susceptibility factors of serum and plasma VEGF levels, the lower proportion of VEGF variability explained by the genetic score in the SFS compared with the FHS and PIVUS study may be related to differences in plasma and serum VEGF concentrations. Finally, although our transcriptomic analysis does provide some support for a functional role of SNPs associated with mRNA levels of VEGF 121 , these results are exploratory and were not corrected for multiple testing. We may have been underpowered for this analysis because of limited sample size and also because VEGF expression was measured on PBMCs only, which are not the sole contributors to circulating VEGF levels. Further studies looking at the association of genetic markers with VEGF expression in other cell types, including endothelial cells, would be of great value.
Clinical Implications
VEGF plays a key role in various diseases including atherosclerosis, inflammatory and neurodegenerative disorders, and cancer. 1 Anti-VEGF and proangiogenic VEGF-based treatments have recently been developed for several therapeutic indications. 19 -23 The identification of polymorphisms linked to VEGF levels could help in identifying patients who are more likely to respond favorably to such treatments. These therapies can have major side effects, 24 and optimizing the risk-benefit ratio of their administration could lead to substantial improvements in patient care. The discovery of trans-acting genetic variants influencing VEGF levels could also spur the discovery of new molecular targets for proangiogenic or antiangiogenic therapies.
Conclusions
In a large population-based sample of European ancestry, we identified novel genetic variants associated with circulating VEGF levels on chromosomes 6p21.1, 8q23.1, and 9p24.2, which explain almost half of the observed phenotypic variation.
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Novelty and Significance
What Is Known?
• Circulating level of vascular endothelial growth factor (VEGF) is a heritable trait (60% to 80% heritability). The underlying genetic variants have not been identified.
• VEGF has important physiological and pathophysiological roles in promoting and supporting angiogenesis, as a vasodilator and neurotrophic factor. It also promotes atherosclerosis.
• VEGF antagonists are used to treat macular degeneration and certain cancers.
• VEGF agonists may help treat limb ischemia.
What New Information Does This Article Contribute?
• Four independent novel loci are identified, using an unbiased genome-wide association study approach combined with messenger RNA expression and Ingenuity pathway analysis.
• The novel loci explain nearly half the observed variation in serum VEGF levels, in population-based samples of European descent, who were free of cardiovascular disease.
• Two novel loci are downstream of the VEGFA gene on chromosome 6 and may be transcription regulators.
• Two other novel "trans" loci are located on chromosomes 8q23.1 and 9p24.2. Potential candidate genes at these loci are zinc finger protein multitype 2 (ZFPM2) and very low-density lipoprotein receptor (VLDLR).
VEGF has a pathophysiological role in atherosclerosis, inflammatory and neurodegenerative disorders, and cancer. Circulating VEGF level is a strongly heritable trait, but the underlying genetic variants are unknown. Understanding the genetic determinants of VEGF levels is of potential pharmacogenomic importance as VEGF antagonists (with interindividual differences in toxicity and efficacy) are used to treat macular degeneration, colon cancer, and other conditions. We undertook genome-wide association study of serum VEGF levels in 3527 communitybased, Framingham Heart Study participants and replicated our findings in 2 other healthy samples, the Stanislas Family Study and the Prospective Investigation of Vasculature in Uppsala Seniors. We identified 4 novel loci across 3 chromosomes: 6p21.1, 8q23.1, and 9p24.2, which together explain 48% of the observed variability in serum VEGF. In exploratory analyses, 6 of 24 SNPs studied were associated with peripheral blood mononuclear cell messenger RNA expression of VEGF . Further, Ingenuity pathway analyses revealed that genes adjacent to the 2 trans loci, ZFPM2 on chromosome 8 and VLDLR on chromosome 9, are linked to VEGF along plausible biological pathways. These findings highlight the potential importance of distant regulatory regions in determining biomarker levels. These results might help target VEGF-based treatments and spur the discovery of new molecular targets for proangiogenic or antiangiogenic therapies.
